Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer

BACKGROUND AND OBJECTIVE: Tislelizumab is a programmed cell death protein-1 (PD-1) inhibitor. Tislelizumab plus chemotherapy as first-line option for advanced non-squamous non-small cell lung cancer (NSCLC), compared with chemotherapy alone, resulted in significantly prolonged survival outcomes; how...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xueyan, Chen, Xiaoyu, Li, Huijuan, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922748/
https://www.ncbi.nlm.nih.gov/pubmed/36794070
http://dx.doi.org/10.3389/fpubh.2023.1009920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922748/
https://www.ncbi.nlm.nih.gov/pubmed/36794070
http://dx.doi.org/10.3389/fpubh.2023.1009920

Ejemplares similares